Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) have been given a consensus rating of “Moderate Buy” by the thirteen research firms that are currently covering the company, MarketBeat Ratings reports. Four analysts have rated the stock with a hold recommendation, eight have assigned a buy recommendation and one has assigned a strong […]

Leave a Reply

Your email address will not be published.

Previous post Foo Fighters pull out of Conn. music festival amid Dave Grohl scandal
Next post The Chemours Company (NYSE:CC) Receives $26.75 Consensus Target Price from Brokerages